Dabigatran: The anticoagulant we have long expected?
dc.creator | Tagarakis, G. I. | en |
dc.creator | Karangelis, D. | en |
dc.creator | Daskalopoulos, M. E. | en |
dc.creator | Tsilimingas, N. B. | en |
dc.date.accessioned | 2015-11-23T10:49:23Z | |
dc.date.available | 2015-11-23T10:49:23Z | |
dc.date.issued | 2010 | |
dc.identifier | 10.2174/157489010793351926 | |
dc.identifier.issn | 15748901 | |
dc.identifier.uri | http://hdl.handle.net/11615/33536 | |
dc.description.abstract | Many researchers have until now united their efforts in the endeavor to discover new anticoagulants, which would be simpler to use and safer to administer, so that patients would avoid both thromboembolic events as well as life threatening episodes of bleeding. One of these agents, that is hereby presented along with patents, is dabigatran, which promises much for the future, despite the fact that time and the awaited results of ongoing trials will be necessary for its establishment as a first-line anticoagulant. More specifically, based on the major trials of RELY and RECOVER, we could state that dabigatran has presented satisfactory outcomes in terms of bleeding and prevention of venous thromboembolism. © 2010 Bentham Science Publishers Ltd. | en |
dc.source.uri | http://www.scopus.com/inward/record.url?eid=2-s2.0-78649982650&partnerID=40&md5=4ced39053fae22adedfeb9ecb0e89269 | |
dc.subject | Anticoagulant & | en |
dc.subject | Dabigatran | en |
dc.subject | Prevention | en |
dc.subject | acetylsalicylic acid | en |
dc.subject | amiodarone | en |
dc.subject | clarithromycin | en |
dc.subject | cyclosporin | en |
dc.subject | dabigatran etexilate | en |
dc.subject | enoxaparin | en |
dc.subject | esomeprazole | en |
dc.subject | garlic extract | en |
dc.subject | ginger extract | en |
dc.subject | ibuprofen | en |
dc.subject | lansoprazole | en |
dc.subject | macrolide | en |
dc.subject | metronidazole | en |
dc.subject | mifepristone | en |
dc.subject | nonsteroid antiinflammatory agent | en |
dc.subject | omeprazole | en |
dc.subject | pantoprazole | en |
dc.subject | pradax | en |
dc.subject | protamine sulfate | en |
dc.subject | quinidine | en |
dc.subject | rifampicin | en |
dc.subject | ritonavir | en |
dc.subject | unclassified drug | en |
dc.subject | verapamil | en |
dc.subject | vitamin K group | en |
dc.subject | warfarin | en |
dc.subject | abdominal discomfort | en |
dc.subject | abdominal pain | en |
dc.subject | anticoagulation | en |
dc.subject | article | en |
dc.subject | bleeding | en |
dc.subject | clinical trial | en |
dc.subject | diarrhea | en |
dc.subject | drug indication | en |
dc.subject | drug safety | en |
dc.subject | dyspepsia | en |
dc.subject | fatigue | en |
dc.subject | human | en |
dc.subject | nausea | en |
dc.subject | osteoporosis | en |
dc.subject | patent | en |
dc.subject | pharmacodynamics | en |
dc.subject | priority journal | en |
dc.subject | skin disease | en |
dc.subject | vein thrombosis | en |
dc.subject | venous thromboembolism | en |
dc.subject | vomiting | en |
dc.subject | Administration, Oral | en |
dc.subject | Anticoagulants | en |
dc.subject | Benzimidazoles | en |
dc.subject | beta-Alanine | en |
dc.subject | Humans | en |
dc.title | Dabigatran: The anticoagulant we have long expected? | en |
dc.type | journalArticle | en |
Αρχεία σε αυτό το τεκμήριο
Αρχεία | Μέγεθος | Τύπος | Προβολή |
---|---|---|---|
Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο. |